Abbott Laboratories (ABT) Capital Expenditures (2009 - 2026)

Abbott Laboratories has disclosed Capital Expenditures across 18 years of filings, most recently posting $399.0 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $399.0 million, down 17.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 9.03% YoY), and the FY2025 annual result was $2.2 billion, down 1.63% from the prior year.
• Capital Expenditures came in at $399.0 million for Q1 2026 at Abbott Laboratories, down from $689.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $755.0 million in Q4 2023 to a low of $321.0 million in Q1 2022.
• The 5-year median for Capital Expenditures is $502.0 million (2025), against an average of $515.1 million.
• Across the five-year window, Capital Expenditures fell 19.14% in 2022 and surged 33.77% in 2023, its largest moves.
• Abbott Laboratories' Capital Expenditures stood at $610.0 million in 2022, then rose by 23.77% to $755.0 million in 2023, then fell by 4.64% to $720.0 million in 2024, then slipped by 4.31% to $689.0 million in 2025, then slumped by 42.09% to $399.0 million in 2026.
• The last three Capital Expenditures figures came in at $399.0 million (Q1 2026), $689.0 million (Q4 2025), and $496.0 million (Q3 2025), per Business Quant data.